SCHEMBL1344820

SCHEMBL1344820

CCOC(=O)C(=CN(c1cc(F)c(F)c(F)c1)C1CCOCC1)C(=O)OCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.37
KDM4E B2RXH2 3/20 0.37
POLB P06746 2/20 0.37
ENPP2 Q13822 1/20 0.36
MAPT P10636 5/20 0.36
LMNA P02545 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PDE4B Q07343 1/20 0.34
ALDH1A1 P00352 3/20 0.34
GAA P10253 3/20 0.34
HPGD P15428 2/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
S1PR4 O95977 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25069399 0.92 NPSR1 (0.40) NPSR1KDM4EPOLBMAPTLMNA
SCHEMBL262000 0.89 MAPT (0.38) NPSR1KDM4EMAPTLMNAMEN1
SCHEMBL8645991 0.80 MEN1 (0.41) NPSR1KDM4EMAPTLMNAMEN1
SCHEMBL7938381 0.75 KDM4E (0.47) KDM4EMAPTLMNAKMT2AALDH1A1
SCHEMBL8626320 0.74 ALDH1A1 (0.40) NPSR1KDM4EPOLBMAPTLMNA
SCHEMBL8625558 0.74 KMT2A (0.40) NPSR1POLBMAPTLMNAMEN1
SCHEMBL6651194 0.73 MAPT (0.39) NPSR1KDM4EPOLBMAPTLMNA
SCHEMBL1243769 0.72 MAPT (0.40) NPSR1KDM4EPOLBMAPTLMNA
SCHEMBL7938828 0.71 KDM4E (0.48) KDM4EMAPTLMNAKMT2AALDH1A1
SCHEMBL6647935 0.70 NPSR1 (0.37) NPSR1KDM4EPOLBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013182-B1 AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2013-09-04 EP disclosed
US-8063221-B2 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-8063221-B2 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-8063221-B2 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
EP-2383271-A1 Aminoquinolones as GSK-3 Inhibitors Kyorin Pharmaceutical Co., Ltd. (JP) 2011-11-02 EP disclosed
EP-2383271-A1 Aminoquinolones as GSK-3 Inhibitors Kyorin Pharmaceutical Co., Ltd. (JP) 2011-11-02 EP disclosed
US-20070254866-A1 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
US-20070254866-A1 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254866-A1 Aminoquinolones as GSK-3 inhibitors GSK3B, GSK3A, GSKIP NPSR1 4749/4885KDM4E 403/4885POLB 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.